Medi-Science R & D Framework (i2i)

The project concerns the promoter’s Research and Development expenditures in medical care and biotechnology (antibodies and cell therapy) and upgrading of existing manufacturing facilities for dialysis and products.

Objectives

The research activities aim at the innovation of high-quality products and new therapy approaches in line with the Bank’s Innovation 2010 Initiative. The promoter’s main production facilities in dialysis technology are located in Objective 2 areas for allocations from the EU Structural Fund. The project will result in creation of some new jobs while safeguarding existing employment.

Comments

Fabrication of medical equipment and pharmaceuticals.

Sector(s)

Industry

Proposed EIB finance (Approximate amount)

EUR 232m.

Total cost (Approximate amount)

Up to EUR 330m.

Environmental aspects

Compliance with EU environmental directives and national laws shall be ensured.

Procurement

Procurement regulations do not apply to this private industry project. The promoter carries out competitive enquiries among potential suppliers for goods and services, as is usual in the industry.

Status

Signed - 13/07/2005.

Disclaimer

Before financing approval by the Board of Directors, and before loan signature, projects are under appraisal and negotiation. Therefore data provided on this page is indicative and cannot be considered to represent official EIB Policy (see also the Explanatory notes).

Projects

Research and development in fields of medical care and biotechnology in Bad Homburg and Munich; upgrading and expansion of plants manufacturing dialysis products in Objective 2 areas

E-mail

General enquiries and comments

The EIB is committed to open communication and encourages constructive stakeholder input regarding its activities. Enquiries and comments regarding the EIB’s involvement in a project or the financing facilities, activities, organisation and objectives of the EIB, can be sent to the EIB Infodesk.

Alternatively, EIB can also be contacted through its external offices.

Queries regarding details of a specific project, in particular when EIB loan is under appraisal, should be preferably addressed directly to project promoters.

Media enquiries

Media related enquiries can be addressed to the EIB Press Office. Please also visit our Press Corner.

Complaints mechanism

Any complaint regarding alleged maladministration can be lodged to EIB Complaints Mechanism. The European Ombudsman acts as an independent external accountability mechanism of the EIB.

Zero-tolerance against fraud and corruption

The EIB has a zero-tolerance policy on fraud or corruption. To report allegations of fraud or corruption in EIB-financed projects, please contact the Fraud and Investigation division. All complaints will be treated as strictly confidential, and are handled in line with EIB investigation procedures and the Anti-Fraud Policy.

EIB Transparency Policy

The EIB is committed to achieving the highest possible level of transparency. The EIB Transparency Policy sets out how EIB discloses information and consults with its stakeholders so as to promote better awareness and understanding of its strategies, policies and operations.

Guide to procurement

This Guide applies specifically to those components of a project identified for the Bank's financing.